Q2 2024 · 13F-HR
Paradigm Biocapital Advisors LPholdings as filed
Filed 2024-08-14 · accession 0001855655-24-000009
$2.61B
Reported value
35
Positions
2024-06-30
Period end
Holdings as filed
| CUSIP | Ticker | Issuer | Value | % port. | Shares | Class | Voting |
|---|---|---|---|---|---|---|---|
| 670703107 | NUVL | NUVALENT INC | $346.8M | 13.3% | 4,571,678 | Common | SOLE |
| 04016X101 | ARGX | ARGENX SE | $231.4M | 8.86% | 538,139 | Common | SOLE |
| 03940C100 | ACLXGBX | ARCELLX INC | $212.4M | 8.13% | 3,848,095 | Common | SOLE |
| 76155X100 | RVMD | REVOLUTION MEDICINES INC | $204.1M | 7.81% | 5,259,089 | Common | SOLE |
| 803607100 | SRPT | SAREPTA THERAPEUTICS INC | $149.7M | 5.73% | 947,574 | Common | SOLE |
| 254604101 | IRON | DISC MEDICINE INC | $121.9M | 4.67% | 2,704,718 | Common | SOLE |
| N5749R100 | 2GH | MERUS N V | $119.5M | 4.57% | 2,019,814 | Common | SOLE |
| 22663K107 | CRNX | CRINETICS PHARMACEUTICALS IN | $112.6M | 4.31% | 2,513,302 | Common | SOLE |
| 15678U128 | CERE1EUR | CEREVEL THERAPEUTICS HLDNG I | $95.3M | 3.65% | 2,330,508 | Common | SOLE |
| 50127T109 | KURA | KURA ONCOLOGY INC | $93.5M | 3.58% | 4,539,381 | Common | SOLE |
| 04351P101 | ASNDUSD | ASCENDIS PHARMA A/S | $90.6M | 3.47% | 664,307 | Common | SOLE |
| 68062P106 | OLMA | OLEMA PHARMACEUTICALS INC | $85.5M | 3.27% | 7,903,600 | Common | SOLE |
| 98420N105 | XENE | XENON PHARMACEUTICALS INC | $79.7M | 3.05% | 2,043,280 | Common | SOLE |
| 87650L103 | TARS | TARSUS PHARMACEUTICALS INC | $66.2M | 2.53% | 2,435,416 | Common | SOLE |
| 47103J105 | JANX | JANUX THERAPEUTICS INC | $65.5M | 2.51% | 1,564,452 | Common | SOLE |
| 04335A105 | ARVN | ARVINAS INC | $64.9M | 2.48% | 2,438,149 | Common | SOLE |
| 52490G102 | LEGN | LEGEND BIOTECH CORP | $53.3M | 2.04% | 1,203,308 | Common | SOLE |
| 92243G108 | PCVX | VAXCYTE INC | $47.4M | 1.81% | 627,202 | Common | SOLE |
| 984241109 | YMABUSD | Y-MABS THERAPEUTICS INC | $46.8M | 1.79% | 3,870,594 | Common | SOLE |
| 28036F105 | EWTX | EDGEWISE THERAPEUTICS INC | $41.9M | 1.60% | 2,325,449 | Common | SOLE |
| N44445109 | IMTX | IMMATICS N.V | $39.8M | 1.52% | 3,421,965 | Common | SOLE |
| 92790C104 | VRDN | VIRIDIAN THERAPEUTICS INC | $37.7M | 1.44% | 2,896,349 | Common | SOLE |
| 45258J102 | IMVT | IMMUNOVANT INC | $36.0M | 1.38% | 1,362,827 | Common | SOLE |
| 19240Q201 | COGT | COGENT BIOSCIENCES INC | $30.6M | 1.17% | 3,624,342 | Common | SOLE |
| 10806X102 | BBIO | BRIDGEBIO PHARMA INC | $27.6M | 1.06% | 1,089,492 | Common | SOLE |
| 230031106 | CGEM | CULLINAN THERAPEUTICS INC | $26.9M | 1.03% | 1,542,805 | Common | SOLE |
| 29479A108 | ERAS | ERASCA INC | $17.1M | 0.65% | 7,250,000 | Common | SOLE |
| 20451W101 | CMPS | COMPASS PATHWAYS PLC | $14.1M | 0.54% | 2,335,926 | Common | SOLE |
| 03770N101 | APGE | APOGEE THERAPEUTICS INC | $13.0M | 0.50% | 330,000 | Common | SOLE |
| 925050106 | VRNA | VERONA PHARMA PLC | $10.4M | 0.40% | 721,087 | Common | SOLE |
| 00166B105 | ALXO | ALX ONCOLOGY HLDGS INC | $9.5M | 0.36% | 1,575,605 | Common | SOLE |
| 46489V302 | CATX | PERSPECTIVE THERAPEUTICS INC | $9.2M | 0.35% | 919,692 | Common | SOLE |
| 929033108 | — | VOR BIOPHARMA INC | $6.5M | 0.25% | 6,457,293 | Common | SOLE |
| 004890109 | ACRV | ACRIVON THERAPEUTICS INC | $3.8M | 0.15% | 659,724 | Common | SOLE |
| 89854M101 | TCRX | TSCAN THERAPEUTICS INC | $2.1M | 0.08% | 353,886 | Common | SOLE |
Source: SEC EDGAR · raw 13F holdings as filed. The Class column shows the option type when reported (Put/Call) or Common when the issuer's equity is held directly. 13F discloses long positions only.